• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Piper Sandler initiated coverage on enGene Holdings with a new price target

    2/18/25 7:08:31 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email
    Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00
    Get the next $ENGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Leadership Updates

    Live Leadership Updates

    See more
    • enGene Names Amy Pott as Chief Global Commercialization Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

      5/28/25 7:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chief Technology Officer (CTO) and member of the corporate leadership team. In addition, enGene Co-Founder and former CTO, Anthony Cheung, Ph.D., will transition to the role of Chief Scientific Officer, succeeding James Sullivan, MSc, Ph.D. Ms. Connolly's career spans

      10/21/24 8:45:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Announces Appointment of Ron Cooper as Chief Executive Officer

      Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced succession plan for Jason Hanson, who will remain in service to the Company as a strategi

      7/24/24 6:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Financials

    Live finance-specific insights

    See more
    • enGene Reports First Quarter 2025 Financial Results and Provides Business Update

      Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl

      3/10/25 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Reports Full Year 2024 Financial Results and Provides a Business Update

      BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026 All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol Additional preliminary data from pivotal cohort anticipated in 2H 2025 Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder

      12/19/24 4:05:00 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

      Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results Favorable tolerability profile with no drug-related discontinuations Detalimogene's profile to date supports its potential as a foundational therapy for NMIBC enGene to host a conference call to discuss preliminary data today at 8:00 a.m. ET enGene Holdings Inc. (NASDAQ:ENGN), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with

      9/26/24 6:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 5:48:15 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 5:05:21 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

      SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

      11/14/24 7:53:57 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ENGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ENGN
    SEC Filings

    See more
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      11/1/24 4:15:08 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/18/24 4:15:05 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/1/24 8:02:44 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on enGene Holdings with a new price target

      Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

      2/18/25 7:08:31 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings downgraded by UBS with a new price target

      UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

      2/14/25 8:16:16 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on enGene Holdings with a new price target

      H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00

      12/23/24 7:22:45 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by enGene Holdings Inc.

      DEF 14A - enGene Holdings Inc. (0001980845) (Filer)

      5/9/25 4:05:24 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by enGene Holdings Inc.

      S-8 - enGene Holdings Inc. (0001980845) (Filer)

      3/10/25 4:27:39 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by enGene Holdings Inc.

      10-Q - enGene Holdings Inc. (0001980845) (Filer)

      3/10/25 4:10:30 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Pott Amy

      3 - enGene Holdings Inc. (0001980845) (Issuer)

      5/29/25 5:30:57 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Pruthi Raj Som

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:46:11 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Strategy & Ops. Ofc Nichols Alexander Julian

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      1/31/25 4:44:27 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enGene to Present at the Jefferies Global Healthcare Conference

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lea

      5/29/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Names Amy Pott as Chief Global Commercialization Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

      5/28/25 7:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene to Participate in Upcoming Investor Conferences

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025 Time: 11:30 a.m. ET Format: Fireside Chat A live webcast of these presentations can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotec

      4/28/25 8:00:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care